Future medicinal chemistry最新文献

筛选
英文 中文
Synthesis of new coumarin derivatives and assessment of their antimicrobial efficacy. 香豆素新衍生物的合成及其抑菌效果评价。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-12 DOI: 10.1080/17568919.2024.2437974
Basma Saad Baaiu, Nashwa M Saleh, Abdulrahman Faraj Alshref Aldirsi, Anhar Abdel-Aziem
{"title":"Synthesis of new coumarin derivatives and assessment of their antimicrobial efficacy.","authors":"Basma Saad Baaiu, Nashwa M Saleh, Abdulrahman Faraj Alshref Aldirsi, Anhar Abdel-Aziem","doi":"10.1080/17568919.2024.2437974","DOIUrl":"10.1080/17568919.2024.2437974","url":null,"abstract":"<p><strong>Aim: </strong>Developing new antimicrobial agents in response to the urgent challenge of antimicrobial resistance.</p><p><strong>Methods: </strong>Synthesis of the targeted coumarins, elucidation of their structures using spectroscopic tools, and investigation of their antimicrobial activity.</p><p><strong>Results: </strong>Coumarin-pyrazole <b>11</b> with CF<sub>3</sub> in the 3-position of the pyrazole ring displayed the lowest minimum inhibitory concentrations (MICs) and the minimum bactericidal concentrations (MBCs) with values of 1.95 and 15.6 µg/ml, respectively, against <i>Bacillus pumilis</i>. In addition, it exhibited the best inhibitory activity against <i>Saccharomyces cerevisiae</i> (MIC = 3.91 µg/ml) compared to the rest of the derivatives (7.81-62.5 µg/ml). Surprisingly, coumarin <b>14</b> with the S-CH<sub>3</sub> group had higher ability to inhibit the <i>Staphylococcus faecalis</i> strain with an MIC value of <b>1.95 µg/ml</b>, which is twice that of penicillin G (<b>MIC = 3.91 µg/ml</b>). At the same time, compounds <b>6</b>, <b>8</b>, <b>11</b>, <b>16</b>, and penicillin G showed similar activity with an MIC value of <b>3.91 µg/ml</b> against <i>Staphylococcus faecalis</i>. Also, the lowest MIC value (3.91 µg/ml) was obtained for S-CH<sub>3</sub> derivative <b>14</b> against <i>Enterobacter cloacae</i>. Coumarins <b>14</b> and 1,3,4-thiadiazine derivative <b>6</b> recorded the lowest MBC (15.6 µg/ml) against <i>Escherichia coli</i>.</p><p><strong>Conclusion: </strong>Finally, it can be concluded that some designed coumarins have a high potential to act as potent antimicrobial agents. Some of them displayed higher efficacy than or equal to the reference drug.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"9-18"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New thiazolidin-4-ones as anti-cervical cancer agents targeting EGFR: design, synthesis, and computational studies. 靶向EGFR的新型噻唑烷-4- 1抗宫颈癌药物:设计、合成和计算研究
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-09 DOI: 10.1080/17568919.2024.2437976
Wafa A Bawazir, Nesreen S Ahmed, Somaia S Abd El-Karim, Ahmed F El-Sayed, Manal M Anwar
{"title":"New thiazolidin-4-ones as anti-cervical cancer agents targeting EGFR: design, synthesis, and computational studies.","authors":"Wafa A Bawazir, Nesreen S Ahmed, Somaia S Abd El-Karim, Ahmed F El-Sayed, Manal M Anwar","doi":"10.1080/17568919.2024.2437976","DOIUrl":"10.1080/17568919.2024.2437976","url":null,"abstract":"<p><strong>Aim: </strong>A new series of 3,4-dihydronaphthalen-1(2 h)-ylidene)hydrazineylidene)-5-substituted thiazolidin-4-one derivatives were designed and synthesized.</p><p><strong>Results & methodology: </strong>The new compounds were screened for in vitro antitumor activity against Hela cancer cell line. The compounds 7b, 7 h, and 7i produced more potent cytotoxicity than doxorubicin with IC<sub>50</sub> values of 1.83 ± 0.1, 2.54 ± 0.14, 2.75 ± 0.15, and 3.63 ± 0.2 μM, respectively. They also showed a promising safety profile against WI-38 normal cells. In addition, compound 7b produced a promising multi-kinase inhibition against EGFR (WT) while being very selective toward the mutant forms (L858R and T790M) with IC<sub>50</sub> values of 0.099 ± 0.006, 0.064 ± 0.006, and 0.026 ± 0.007 μM, respectively, in comparison to gefitinib and osimertinib. A study of the cell cycle in Hela cells showed that 7b arrests cell cycle in the pre-G1 phase and causes early and late apoptosis. Eventually, the molecular docking results showed that 7b had good-binding interactions with EGFR<sup>WT</sup>, EGFR<sup>L858R</sup>, and EGFR<sup>T790M</sup>.</p><p><strong>Conclusion: </strong>Compound 7b was predicted to have promising oral absorption, good drug-likeness, and low toxicity risks in humans. Moreover, MD simulations confirmed the stable complexes of 7b with EGFR<sup>WT</sup>, EGFRL858R, and EGFR<sup>T790M</sup> (with RMSD 0.12-0.35 nm, RMSF 0.2-0.55 nm, SASA 140-150, and Rg 1.80-2.00 nm).</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"75-91"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing novel indoles as antitubercular agents and simulated annealing-based analysis of their binding with MmpL3. 开发新型抗结核药物吲哚及其与MmpL3结合的模拟退火分析。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-25 DOI: 10.1080/17568919.2024.2444872
Rajdeep Ray, Stutee Das, Sumit Raosaheb Birangal, Helena I Boshoff, Jose Santinni Roma, Manisha Lobo, Raghu Chandrashekhar Hariharapura, G Gautham Shenoy
{"title":"Developing novel indoles as antitubercular agents and simulated annealing-based analysis of their binding with MmpL3.","authors":"Rajdeep Ray, Stutee Das, Sumit Raosaheb Birangal, Helena I Boshoff, Jose Santinni Roma, Manisha Lobo, Raghu Chandrashekhar Hariharapura, G Gautham Shenoy","doi":"10.1080/17568919.2024.2444872","DOIUrl":"10.1080/17568919.2024.2444872","url":null,"abstract":"<p><strong>Aim: </strong>This research aimed to develop novel indole-2-carboxamides as potential antitubercular agents using rational drug design. It also focused on identifying the critical interactions required for these compounds to exhibit effective antitubercular activity.</p><p><strong>Materials and methods: </strong>Novel indole-2-carboxamides targeting MmpL3 were designed based on SAR, synthesized, and tested for their antitubercular and <i>iniBAC</i> induction properties. Classical docking and simulated annealing were utilized to understand protein-ligand binding affinity.</p><p><strong>Results: </strong>Compounds 5c, 5f, and 5i, were active against H37Rv and different MDR and XDR strains of <i>M. tuberculosis. iniBAC</i> promoter induction study indicated that those were inhibitors of MmpL3. Through the docking and simulated annealing studies, we identified key protein-ligand interactions at the MmpL3 binding site.</p><p><strong>Conclusion: </strong>We have identified three potent antitubercular molecules that supposedly act via inhibiting MmpL3. Results from the molecular modeling studies can be used in future drug designing.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"19-34"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel coumarin linked pyrazoles, thiazoles, and thiadiazoles: synthetic strategies and in vitro antimicrobial investigation. 新型香豆素连接的吡唑、噻唑和噻二唑:合成策略和体外抗菌研究。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-26 DOI: 10.1080/17568919.2024.2444867
Salwa A Elsharabasy, Mariam T Sayed, Anhar Abdel-Aziem
{"title":"Novel coumarin linked pyrazoles, thiazoles, and thiadiazoles: synthetic strategies and in vitro antimicrobial investigation.","authors":"Salwa A Elsharabasy, Mariam T Sayed, Anhar Abdel-Aziem","doi":"10.1080/17568919.2024.2444867","DOIUrl":"10.1080/17568919.2024.2444867","url":null,"abstract":"<p><strong>Aim: </strong>Emerging resistance among pathogens necessitates the development of novel antimicrobial agents. As a result, we aimed to synthesize new coumarins and study their antimicrobial activity with the hope of obtaining effective drugs.</p><p><strong>Method: </strong>A series of coumarins were synthesized, characterized, and assessed for antimicrobial activity using broth microdilution and agar diffusion methods against Gram-positive (<i>Bacillus pumilis, Streptococcus faecalis</i>), Gram-negative (<i>Escherichia coli, Enterobacter cloacae</i>) bacteria, and fungi (<i>Saccharomyces cerevisiae, Candida albicans</i>).</p><p><strong>Results: </strong>Pyrazoles <b>15</b> and <b>16</b> revealed promising activities against all bacterial strains with MIC values ranging from 1.95 to 15.6 µg/ml. Notably, pyrazole <b>15</b> with CF<sub>3</sub> in 3-position of pyrazole ring demonstrated higher ability to inhibit <i>Streptococcus faecalis</i> strain with MIC value equal to penicillin G (3.91 µg/ml). It also exhibited the best bactericidal potency against <i>Escherichia coli</i> with MBC value of 15.6 µg/ml while, pyrazole <b>16</b> recorded the same MBC value against <i>Enterobacter cloacae</i>. Pyrazole <b>15</b> demonstrated the strongest antifungal activity against both fungal strains with MIC and MFC values of 15.6, 7.81, 62.5, and 31.3 µg/ml against <i>Saccharomyces cerevisiae</i> and <i>Candida albicans</i>, respectively.</p><p><strong>Conclusion: </strong>These findings underscore the potential of coumarins, particularly compounds <b>15</b> and <b>16</b>, as effective antimicrobial agents and provide critical insights into the design of bioactive molecules.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"183-193"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic targeting of neuroinflammation in methamphetamine use disorder. 甲基苯丙胺使用障碍患者神经炎症的靶向治疗。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-27 DOI: 10.1080/17568919.2024.2447226
Natasha Jeffery, Phooi Yan Mock, Kun Yang, Chau Ling Tham, Daud Ahmad Israf, Hongyuan Li, Xiaohui Wang, Kok Wai Lam
{"title":"Therapeutic targeting of neuroinflammation in methamphetamine use disorder.","authors":"Natasha Jeffery, Phooi Yan Mock, Kun Yang, Chau Ling Tham, Daud Ahmad Israf, Hongyuan Li, Xiaohui Wang, Kok Wai Lam","doi":"10.1080/17568919.2024.2447226","DOIUrl":"10.1080/17568919.2024.2447226","url":null,"abstract":"<p><p>Methamphetamine (METH) is a highly addictive illicit psychostimulant with a significant annual fatality rate. Emerging studies highlight its role in neuroinflammation and a range of neurological disorders. This review examines the current landscape of potential drug targets for managing neuroinflammation in METH use disorders (MUDs), with a particular focus on the rationale behind targeting Toll-like receptor 4 (TLR4), the NLR family pyrin domain containing 3 (NLRP3) inflammasome, and other promising targets. Given the multifactorial neurological effects of METH, including cognitive impairment and neurodegeneration, addressing METH-induced neuroinflammation has shown considerable promise in partially mitigating the damaging effects on the central nervous system and improving behavioral outcomes. This article provides an overview of the existing understanding while charting a promising path forward for developing innovative MUD treatments, focusing on neuroinflammation as a therapeutic target. Targeting neuroinflammation in METH-induced neurological disorders shows significant promise in mitigating cognitive impairment and neurodegeneration, offering a potential therapeutic strategy for improving outcomes in MUD. While challenges remain in optimizing treatments, ongoing research into combination therapies, novel drug delivery systems, and neuroprotective agents suggests a positive outlook for more effective interventions.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"237-257"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, characterization, and enzyme inhibition evaluation of sitagliptin derivatives and their metal complexes. 西格列汀衍生物及其金属配合物的合成、表征及酶抑制评价。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-31 DOI: 10.1080/17568919.2024.2447223
Javed Ahmed, Mohsin Abbas Khan, Saharish Khaliq, Anum Masood, Breena, Mashooq A Bhat, Muhammad Rizwan Khan, Asim Raza, Mohamed A Al-Omar, Farhat Ullah
{"title":"Synthesis, characterization, and enzyme inhibition evaluation of sitagliptin derivatives and their metal complexes.","authors":"Javed Ahmed, Mohsin Abbas Khan, Saharish Khaliq, Anum Masood, Breena, Mashooq A Bhat, Muhammad Rizwan Khan, Asim Raza, Mohamed A Al-Omar, Farhat Ullah","doi":"10.1080/17568919.2024.2447223","DOIUrl":"10.1080/17568919.2024.2447223","url":null,"abstract":"<p><strong>Aims: </strong>This study focuses on the synthesis and characterization of novel sitagliptin derivatives, aiming to develop potent, orally active anti-diabetic agents with minimal side effects for the management of type 2 diabetes mellitus. Copper (II) (SCu1-SCu9) and zinc (II) (SZn1-SZn9) metal complexes of sitagliptin-based derivatives were synthesized via a template reaction.</p><p><strong>Material & method: </strong>The synthesized complexes were comprehensively characterized using elemental analysis, FTIR, UV-Vis, 1 h NMR, and 13C NMR spectroscopy. The biological efficacy of these compounds was assessed through α-amylase and α-glucosidase enzyme inhibition assays, with molecular simulation studies providing additional confirmation of their inhibitory activity.</p><p><strong>Results: </strong>Among the tested derivatives, SD7, SD4, SD3, SD5, and SD9 demonstrated enzyme inhibition profiles comparable to the standard inhibitors. However, the metal complexes exhibited absorption challenges, which may influence their bioavailability.</p><p><strong>Conclusion: </strong>These findings highlight the significant anti-diabetic potential of the synthesized compounds against targeted enzymes, establishing a foundation for their development as lead molecules in future therapeutic research.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"195-207"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the potential of the thioamide group in drug design and development. 释放硫胺类药物在药物设计和开发中的潜力。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-02 DOI: 10.1080/17568919.2024.2435245
Guang Huang, Tomasz Cierpicki, Jolanta Grembecka
{"title":"Unlocking the potential of the thioamide group in drug design and development.","authors":"Guang Huang, Tomasz Cierpicki, Jolanta Grembecka","doi":"10.1080/17568919.2024.2435245","DOIUrl":"10.1080/17568919.2024.2435245","url":null,"abstract":"","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-3"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges. 靶向不可药物蛋白KRAS用于癌症治疗:新的机遇和挑战。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2025-01-01 Epub Date: 2024-12-23 DOI: 10.1080/17568919.2024.2444865
Xin Yang, Xiang Li, Yue-Lin Zhang, Sheng-Nan Zhang, Miao Zhang, Chong Sun, Li Yang, Hong-Min Liu, Shuo Yuan
{"title":"Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges.","authors":"Xin Yang, Xiang Li, Yue-Lin Zhang, Sheng-Nan Zhang, Miao Zhang, Chong Sun, Li Yang, Hong-Min Liu, Shuo Yuan","doi":"10.1080/17568919.2024.2444865","DOIUrl":"10.1080/17568919.2024.2444865","url":null,"abstract":"","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"143-147"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, DFT, ADMET and molecular docking studies of thiazole derived thiazolidinone-based chalcone derivatives: alzheimer's disease current therapies. 噻唑衍生噻唑烷酮类查尔酮衍生物的合成、DFT、ADMET及分子对接研究:阿尔茨海默病目前的治疗方法。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2024-12-04 DOI: 10.1080/17568919.2024.2421158
Muhammad Shahid Nadeem, Jalaluddin Azam Khan, Imran Kazmi, Ehssan Moglad, Muhammad Afzal, Sami I Alzarea, Fazal Rahim, Shoaib Khan, Khushi Muhammad, Gaurav Gupta
{"title":"Synthesis, DFT, ADMET and molecular docking studies of thiazole derived thiazolidinone-based chalcone derivatives: alzheimer's disease current therapies.","authors":"Muhammad Shahid Nadeem, Jalaluddin Azam Khan, Imran Kazmi, Ehssan Moglad, Muhammad Afzal, Sami I Alzarea, Fazal Rahim, Shoaib Khan, Khushi Muhammad, Gaurav Gupta","doi":"10.1080/17568919.2024.2421158","DOIUrl":"https://doi.org/10.1080/17568919.2024.2421158","url":null,"abstract":"<p><strong>Aim: </strong>Nitrogen and sulfur-containing compounds are the core components utilized for synthesis of different heterocyclic moieties.</p><p><strong>Methods & results: </strong>In this research, a series of new analogues containing thiazolidinone have been synthesized <b>(1-20)</b> in order to evaluate their activity against acetylcholinesterase and butyrylcholinesterase. Potent analogues were further subjected for molecular docking in order to study their protein-ligand interactions. The highly active analogues were also subjected for DFT, which confirmed the binding properties, electrical properties, and nature with the targeted enzyme. ADMET analysis also confirms the druglikeness properties of the synthesized series.</p><p><strong>Conclusion: </strong>Analog <b>5</b> (IC<sub>50</sub> = <b>1.2 ± 0.1 µM and 1.8 ± 0.2</b> µM) exhibit excellent inhibition in comparison with the standard drug donepezil in view of inhibiting Alzheimer's disease.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"1-9"},"PeriodicalIF":3.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New 4-amino-3-chloro benzoate ester derivatives as EGFR inhibitors: synthesis, in silico and biological analyses. 作为表皮生长因子受体抑制剂的新型 4-氨基-3-氯苯甲酸酯衍生物:合成、硅学和生物学分析。
IF 3.2 4区 医学
Future medicinal chemistry Pub Date : 2024-12-01 Epub Date: 2024-11-20 DOI: 10.1080/17568919.2024.2431478
Nedaa A Abd Al Rahim, Ammar A Razzak Mahmood, Lubna H Tahtamouni, Mai F AlSakhen, Salem R Yasin, Abdulrahman M Saleh
{"title":"New 4-amino-3-chloro benzoate ester derivatives as EGFR inhibitors: synthesis, in silico and biological analyses.","authors":"Nedaa A Abd Al Rahim, Ammar A Razzak Mahmood, Lubna H Tahtamouni, Mai F AlSakhen, Salem R Yasin, Abdulrahman M Saleh","doi":"10.1080/17568919.2024.2431478","DOIUrl":"10.1080/17568919.2024.2431478","url":null,"abstract":"<p><strong>Aim: </strong>The main goal of this study was to synthesize new derivatives of 4-amino-3-chloro benzoate ester, including 1,3,4-oxadiazole derivatives (<b>N3a-d</b>), benzohydrazone derivatives (<b>N4a-c</b>), and hydrazine-1-carbothioamide derivatives (<b>N5a-d</b>) that target epidermal growth factor receptor (EGFR) tyrosine kinase.</p><p><strong>Materials & methods: </strong>The new derivatives were characterized using various spectroscopic techniques. Docking studies were used to investigate the binding patterns to EGFR, and the anti-proliferative properties were tested in vitro.</p><p><strong>Results: </strong>In silico analysis showed that the hydrazine-1-carbothioamide derivatives (<b>N5a-d</b>) had the best matching pattern with EGFR pharmacophoric queries compared to erlotinib, exhibited a favorable safety profile, and showed the best stability among the tested compounds. Compound <b>N5a</b> induced cytotoxicity in the three cancer cell lines tested (A549, HepG2, and HCT-116), by targeting EGFR and activating caspase 3 and caspase 8, therefore, inducing the extrinsic apoptotic pathway.</p><p><strong>Conclusion: </strong>The results of this study show that compound <b>N5a</b> is a promising cytotoxic compound that inhibits the tyrosine kinase activity of EGFR.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2647-2662"},"PeriodicalIF":3.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信